Correction to: Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

The author of this article wanted to change the ethical approval statement of the originally published version of this article. Correct statement is indicated below.

Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Background: A remarkable therapeutic efficacy has been demonstrated with Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma.

Methods: Seventeen patients with advanced prostate cancer were selected for treatment with Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response.